Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,401.00GBp
20 Mar 2019
Change (% chg)

33.00 (+0.52%)
Prev Close
6,368.00
Open
6,373.00
Day's High
6,467.00
Day's Low
6,373.00
Volume
1,374,066
Avg. Vol
2,122,941
52-wk High
6,467.00
52-wk Low
4,746.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 29.30 32.54
EPS (TTM): 2.34 -- --
ROI: 7.86 14.23 13.82
ROE: 28.47 15.46 15.25

BioNTech hires banks for IPO worth up to $800 million: sources

FRANKFURT BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million as early as this year, people familiar with the plan told Reuters.

13 Mar 2019

UPDATE 2-BioNTech hires banks for IPO worth up to $800 million -sources

* IPO eyed in Q4 or early 2020-sources (Adds BioNTech comment)

13 Mar 2019

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

26 Feb 2019

AstraZeneca's Lynparza meets main goal of late-stage cancer study

Feb 26 British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for pancreatic cancer.

26 Feb 2019

UPDATE 2-FTSE 100 squeezes out gains; ConvaTec drags midcaps

* ConvaTec slumps on mid-caps (Adds company news items, updates to closing prices)

14 Feb 2019

European shares give up three-month highs after shock U.S. data

LONDON European shares gave up three-month highs on Thursday after a surprise sharp decline in U.S. retail sales pulled stocks lower in afternoon trading, spoiling an initially upbeat session that saw blue-chips such as Nestle shine on strong earnings.

14 Feb 2019

UPDATE 2-European shares give up 3-month highs after shock U.S. data

LONDON, Feb 14 European shares gave up three-month highs on Thursday after a surprise sharp decline in U.S. retail sales pulled stocks lower in afternoon trading, spoiling an initially upbeat session that saw blue-chips such as Nestle shine on strong earnings.

14 Feb 2019

CORRECTED-AstraZeneca, Micro Focus lift FTSE 100; midcap ConvaTec sinks

Feb 14 Britain's main index on Thursday held onto a more than four-month high hit in the last session, aided by earnings-driven gains in drugmaker AstraZeneca and software firm Micro Focus and boosted by forecast-beating trade data from China.

14 Feb 2019

European shares hit 3-month highs as Nestle, Airbus, AstraZeneca shine

LONDON, Feb 14 Optimism about U.S.-China trade talks, strong results from Nestle, AstraZeneca and Airbus helped European shares extend their winning streak to hit their highest in three months on Thursday.

14 Feb 2019

New cancer drugs help upbeat AstraZeneca beat forecasts

AstraZeneca forecast a second straight year of sales growth on Thursday, driven by cancer medicines and other new drugs as the British drugmaker recovers from losing major patents.

14 Feb 2019

Earnings vs. Estimates